{"product_id":"scripps-40th-annual-new-treatments-in-chronic-liver-disease-2026-20","title":"Scripps 40th Annual New Treatments in Chronic Liver Disease 2026","description":"\u003ch1 data-section-id=\"1wofc8f\" data-start=\"0\" data-end=\"68\"\u003eScripps 40th Annual New Treatments in Chronic Liver Disease 2026\u003c\/h1\u003e\r\n\u003cp data-start=\"69\" data-end=\"171\"\u003eAdvanced Hepatology Updates in MASH, Viral Hepatitis, Autoimmune Liver Disease \u0026amp; Liver Transplantation\u003c\/p\u003e\r\n\u003cp data-start=\"173\" data-end=\"727\"\u003eChronic liver disease is evolving rapidly as new metabolic syndromes, antiviral therapies, fibrosis-directed treatments, and transplant strategies reshape modern hepatology practice. The \u003cem data-start=\"360\" data-end=\"426\"\u003eScripps 40th Annual New Treatments in Chronic Liver Disease 2026\u003c\/em\u003e program provides a clinically focused review of the latest developments in liver disease diagnosis, therapeutics, and transplant medicine, with particular emphasis on emerging metabolic liver disorders, functional viral hepatitis cures, autoimmune hepatology, and complications of advanced cirrhosis.\u003c\/p\u003e\r\n\u003cp data-start=\"729\" data-end=\"969\"\u003eThis annual Scripps conference explores the changing landscape of hepatology through expert-led discussions, panel reviews, and evidence-based clinical updates designed for physicians managing increasingly complex liver disease populations.\u003c\/p\u003e\r\n\u003cp data-start=\"971\" data-end=\"1004\"\u003eThe educational package includes:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1005\" data-end=\"1128\"\u003e\r\n \t\u003cli data-section-id=\"1p2ib04\" data-start=\"1005\" data-end=\"1028\"\u003e\u003cstrong data-start=\"1007\" data-end=\"1028\"\u003e13 Video Lectures\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1kg6lb6\" data-start=\"1029\" data-end=\"1059\"\u003e\u003cstrong data-start=\"1031\" data-end=\"1059\"\u003e13 Subtitle Files (.vtt)\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1sw4qfg\" data-start=\"1060\" data-end=\"1078\"\u003e\u003cstrong data-start=\"1062\" data-end=\"1078\"\u003e12 PDF Files\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"187uppd\" data-start=\"1079\" data-end=\"1104\"\u003e\u003cstrong data-start=\"1081\" data-end=\"1104\"\u003eTotal Size: 3.48 GB\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"h9kcp2\" data-start=\"1105\" data-end=\"1128\"\u003e\u003cstrong data-start=\"1107\" data-end=\"1128\"\u003eCourse Year: 2026\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1130\" data-end=\"1315\"\u003eThe course reflects how hepatology is shifting from largely supportive management toward precision medicine, targeted biologics, metabolic intervention, and disease-modifying therapies.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"jekqof\" data-start=\"1317\" data-end=\"1365\"\u003eThe Rapid Transformation of Modern Hepatology\u003c\/h2\u003e\r\n\u003cp data-start=\"1367\" data-end=\"1454\"\u003eOver the past decade, hepatology has undergone major transformation due to advances in:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1455\" data-end=\"1667\"\u003e\r\n \t\u003cli data-section-id=\"vpqohr\" data-start=\"1455\" data-end=\"1478\"\u003eAntiviral therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"10igfd3\" data-start=\"1479\" data-end=\"1502\"\u003eFibrosis assessment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"4pedds\" data-start=\"1503\" data-end=\"1545\"\u003eMetabolic liver disease classification\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ghw5xo\" data-start=\"1546\" data-end=\"1572\"\u003eImmunologic treatments\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vmtu7o\" data-start=\"1573\" data-end=\"1600\"\u003eTransplant optimization\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"8eq8cq\" data-start=\"1601\" data-end=\"1628\"\u003eNoninvasive diagnostics\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"quo8c1\" data-start=\"1629\" data-end=\"1667\"\u003eHepatocellular carcinoma therapies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1669\" data-end=\"1737\"\u003eAt the same time, clinicians increasingly face rising prevalence of:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1738\" data-end=\"1901\"\u003e\r\n \t\u003cli data-section-id=\"ug724i\" data-start=\"1738\" data-end=\"1774\"\u003eObesity-associated liver disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"c56494\" data-start=\"1775\" data-end=\"1808\"\u003eAlcohol-related liver disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"dc6p0w\" data-start=\"1809\" data-end=\"1867\"\u003eCombined metabolic and alcohol-associated liver injury\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"8i9dv7\" data-start=\"1868\" data-end=\"1901\"\u003eEnd-stage liver complications\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1903\" data-end=\"2027\"\u003eThe course repeatedly emphasizes that liver disease management now requires broader multidisciplinary integration involving:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2028\" data-end=\"2155\"\u003e\r\n \t\u003cli data-section-id=\"1nvgbsc\" data-start=\"2028\" data-end=\"2045\"\u003eEndocrinology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1bh4opf\" data-start=\"2046\" data-end=\"2066\"\u003eObesity medicine\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ew4ocb\" data-start=\"2067\" data-end=\"2089\"\u003eAddiction medicine\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"9obxko\" data-start=\"2090\" data-end=\"2102\"\u003eOncology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"6pdpg1\" data-start=\"2103\" data-end=\"2126\"\u003eTransplant medicine\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"532z3g\" data-start=\"2127\" data-end=\"2155\"\u003eInterventional radiology\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"i76vt5\" data-start=\"2157\" data-end=\"2195\"\u003eMetALD: An Emerging Clinical Entity\u003c\/h2\u003e\r\n\u003cp data-start=\"2197\" data-end=\"2324\"\u003eOne of the most clinically important topics covered is MetALD (Metabolic dysfunction-associated Alcohol-related Liver Disease).\u003c\/p\u003e\r\n\u003cp data-start=\"2326\" data-end=\"2431\"\u003eThis emerging classification reflects the growing recognition that many patients demonstrate overlapping:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2432\" data-end=\"2528\"\u003e\r\n \t\u003cli data-section-id=\"3mjmpe\" data-start=\"2432\" data-end=\"2457\"\u003eMetabolic dysfunction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gcbbs2\" data-start=\"2458\" data-end=\"2490\"\u003eObesity-related liver injury\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vkh93q\" data-start=\"2491\" data-end=\"2528\"\u003eAlcohol-associated hepatic damage\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2530\" data-end=\"2593\"\u003erather than fitting into purely isolated diagnostic categories.\u003c\/p\u003e\r\n\u003cp data-start=\"2595\" data-end=\"2616\"\u003eThe lectures examine:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2617\" data-end=\"2741\"\u003e\r\n \t\u003cli data-section-id=\"14cdxq4\" data-start=\"2617\" data-end=\"2640\"\u003eDiagnostic criteria\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"d1ddlf\" data-start=\"2641\" data-end=\"2664\"\u003eRisk stratification\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1d8r3yp\" data-start=\"2665\" data-end=\"2688\"\u003eDisease progression\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"10qi1z7\" data-start=\"2689\" data-end=\"2715\"\u003eMetabolic risk factors\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1to9eo6\" data-start=\"2716\" data-end=\"2741\"\u003eManagement strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2743\" data-end=\"2940\"\u003eIn practice, distinguishing metabolic and alcohol-related contributions to liver disease can be challenging because both pathways frequently coexist and synergistically worsen fibrosis progression.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"uao1wz\" data-start=\"2942\" data-end=\"2983\"\u003eMASH Cirrhosis \u0026amp; Disease Reversibility\u003c\/h2\u003e\r\n\u003cp data-start=\"2985\" data-end=\"3061\"\u003eThe MASH (Metabolic dysfunction-associated Steatohepatitis) sessions review:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3062\" data-end=\"3211\"\u003e\r\n \t\u003cli data-section-id=\"19inog4\" data-start=\"3062\" data-end=\"3086\"\u003eFibrosis progression\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"10ekeeb\" data-start=\"3087\" data-end=\"3114\"\u003eCirrhosis reversibility\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"19nfeuc\" data-start=\"3115\" data-end=\"3151\"\u003eEmerging anti-fibrotic therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1chrcng\" data-start=\"3152\" data-end=\"3183\"\u003eWeight reduction strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"huzgdk\" data-start=\"3184\" data-end=\"3211\"\u003eMetabolic interventions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3213\" data-end=\"3417\"\u003eOne of the more important evolving concepts in hepatology is the possibility that even advanced fibrosis and compensated cirrhosis may demonstrate partial reversibility under certain treatment conditions.\u003c\/p\u003e\r\n\u003cp data-start=\"3419\" data-end=\"3439\"\u003eThe course explores:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3440\" data-end=\"3605\"\u003e\r\n \t\u003cli data-section-id=\"lik8nr\" data-start=\"3440\" data-end=\"3471\"\u003eHistologic improvement data\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"nzke7q\" data-start=\"3472\" data-end=\"3499\"\u003eClinical trial evidence\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"he5myw\" data-start=\"3500\" data-end=\"3527\"\u003ePharmacologic therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ka5rsf\" data-start=\"3528\" data-end=\"3555\"\u003eLifestyle interventions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1md6t8o\" data-start=\"3556\" data-end=\"3605\"\u003eBariatric and obesity medicine considerations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"ksdfsg\" data-start=\"3607\" data-end=\"3643\"\u003eObesity Treatment \u0026amp; Liver Disease\u003c\/h2\u003e\r\n\u003cp data-start=\"3645\" data-end=\"3760\"\u003eThe obesity medicine discussions appropriately recognize obesity as a central driver of modern hepatology practice.\u003c\/p\u003e\r\n\u003cp data-start=\"3762\" data-end=\"3777\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3778\" data-end=\"3939\"\u003e\r\n \t\u003cli data-section-id=\"v3bob8\" data-start=\"3778\" data-end=\"3808\"\u003eWeight reduction therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1i92531\" data-start=\"3809\" data-end=\"3836\"\u003eGLP-1 receptor agonists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"7trqbc\" data-start=\"3837\" data-end=\"3870\"\u003eMetabolic syndrome management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1a4g742\" data-start=\"3871\" data-end=\"3902\"\u003eHepatic steatosis reduction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"6ozijr\" data-start=\"3903\" data-end=\"3939\"\u003eCardiometabolic risk improvement\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3941\" data-end=\"4042\"\u003eAs obesity-related liver disease becomes increasingly prevalent worldwide, clinicians must integrate:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4043\" data-end=\"4147\"\u003e\r\n \t\u003cli data-section-id=\"rd5mlv\" data-start=\"4043\" data-end=\"4067\"\u003eNutrition management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"15gsh3s\" data-start=\"4068\" data-end=\"4089\"\u003eEndocrine therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vg9vsd\" data-start=\"4090\" data-end=\"4123\"\u003eCardiovascular risk reduction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1fx8jil\" data-start=\"4124\" data-end=\"4147\"\u003eBehavioral medicine\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4149\" data-end=\"4187\"\u003einto liver disease treatment planning.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"1q7rjq7\" data-start=\"4189\" data-end=\"4236\"\u003eViral Hepatitis \u0026amp; Functional Cure Strategies\u003c\/h2\u003e\r\n\u003cp data-start=\"4238\" data-end=\"4286\"\u003eThe viral hepatitis sessions provide updates on:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4287\" data-end=\"4420\"\u003e\r\n \t\u003cli data-section-id=\"17bztk\" data-start=\"4287\" data-end=\"4319\"\u003eHepatitis B functional cures\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"11jdsbb\" data-start=\"4320\" data-end=\"4346\"\u003eHepatitis C management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"lns55e\" data-start=\"4347\" data-end=\"4385\"\u003eDelta hepatitis treatment advances\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1seqnw8\" data-start=\"4386\" data-end=\"4420\"\u003eAntiviral therapy optimization\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4422\" data-end=\"4536\"\u003eThe concept of “functional cure” in hepatitis B represents one of the most important evolving areas in hepatology.\u003c\/p\u003e\r\n\u003cp data-start=\"4538\" data-end=\"4557\"\u003eThe course reviews:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4558\" data-end=\"4686\"\u003e\r\n \t\u003cli data-section-id=\"17r7109\" data-start=\"4558\" data-end=\"4588\"\u003eNovel antiviral strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1bqxijr\" data-start=\"4589\" data-end=\"4618\"\u003eImmune-targeted therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"28jdfr\" data-start=\"4619\" data-end=\"4646\"\u003eViral suppression goals\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"9u8ueg\" data-start=\"4647\" data-end=\"4686\"\u003eLong-term monitoring considerations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4688\" data-end=\"4870\"\u003eThe delta hepatitis discussions are particularly relevant because HDV remains one of the most aggressive viral liver diseases, historically associated with limited treatment options.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"yqwirb\" data-start=\"4872\" data-end=\"4907\"\u003eAutoimmune Liver Disease Updates\u003c\/h2\u003e\r\n\u003cp data-start=\"4909\" data-end=\"4952\"\u003eThe autoimmune hepatology sections examine:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4953\" data-end=\"5100\"\u003e\r\n \t\u003cli data-section-id=\"18lp70f\" data-start=\"4953\" data-end=\"4977\"\u003eAutoimmune hepatitis\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1o4dihj\" data-start=\"4978\" data-end=\"5015\"\u003ePrimary biliary cholangitis (PBC)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"xo3y2d\" data-start=\"5016\" data-end=\"5056\"\u003ePrimary sclerosing cholangitis (PSC)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1mzwb4z\" data-start=\"5057\" data-end=\"5077\"\u003eNovel biomarkers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"162cgwl\" data-start=\"5078\" data-end=\"5100\"\u003eEmerging therapies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5102\" data-end=\"5287\"\u003eAutoimmune liver diseases remain diagnostically and therapeutically complex because disease activity, fibrosis progression, and treatment response can vary substantially among patients.\u003c\/p\u003e\r\n\u003cp data-start=\"5289\" data-end=\"5391\"\u003eThe course highlights evolving therapeutic approaches and updated understanding of disease mechanisms.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"bcyap2\" data-start=\"5393\" data-end=\"5428\"\u003eDrug-Induced Liver Injury (DILI)\u003c\/h2\u003e\r\n\u003cp data-start=\"5430\" data-end=\"5460\"\u003eThe DILI discussions focus on:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5461\" data-end=\"5586\"\u003e\r\n \t\u003cli data-section-id=\"udh9ix\" data-start=\"5461\" data-end=\"5486\"\u003eDiagnostic evaluation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"10w4njb\" data-start=\"5487\" data-end=\"5510\"\u003ePattern recognition\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"10a5fa3\" data-start=\"5511\" data-end=\"5548\"\u003eMedication-related hepatotoxicity\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"h402yi\" data-start=\"5549\" data-end=\"5586\"\u003eDifferential diagnosis challenges\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5588\" data-end=\"5702\"\u003eDrug-induced liver injury remains one of the most difficult areas in hepatology because presentations often mimic:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5703\" data-end=\"5805\"\u003e\r\n \t\u003cli data-section-id=\"yn8gfb\" data-start=\"5703\" data-end=\"5722\"\u003eViral hepatitis\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1qjpg2k\" data-start=\"5723\" data-end=\"5745\"\u003eAutoimmune disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1bvgy8u\" data-start=\"5746\" data-end=\"5771\"\u003eCholestatic disorders\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"mmq91o\" data-start=\"5772\" data-end=\"5805\"\u003eAcute liver failure syndromes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5807\" data-end=\"5887\"\u003eThe lectures emphasize careful clinical reasoning and exclusion-based diagnosis.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"1hotqr4\" data-start=\"5889\" data-end=\"5922\"\u003eHepatocellular Carcinoma (HCC)\u003c\/h2\u003e\r\n\u003cp data-start=\"5924\" data-end=\"5948\"\u003eThe HCC sections review:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5949\" data-end=\"6094\"\u003e\r\n \t\u003cli data-section-id=\"ygla5y\" data-start=\"5949\" data-end=\"5974\"\u003eLiver mass evaluation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"73i0op\" data-start=\"5975\" data-end=\"5999\"\u003eScreening strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1w3oaii\" data-start=\"6000\" data-end=\"6031\"\u003eEmerging systemic therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"65dsbb\" data-start=\"6032\" data-end=\"6064\"\u003eMultidisciplinary management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gs5vn4\" data-start=\"6065\" data-end=\"6094\"\u003eTransplant considerations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6096\" data-end=\"6182\"\u003eHepatocellular carcinoma management has changed dramatically with the introduction of:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6183\" data-end=\"6272\"\u003e\r\n \t\u003cli data-section-id=\"1a6v2os\" data-start=\"6183\" data-end=\"6213\"\u003eImmunotherapy combinations\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"fml471\" data-start=\"6214\" data-end=\"6236\"\u003eTargeted therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1e0gzb3\" data-start=\"6237\" data-end=\"6272\"\u003eLocoregional treatment advances\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6274\" data-end=\"6400\"\u003eThe course explores how evolving oncology therapies are reshaping prognosis and treatment sequencing in advanced liver cancer.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"1srlx6n\" data-start=\"6402\" data-end=\"6435\"\u003eAscites \u0026amp; Hepatorenal Syndrome\u003c\/h2\u003e\r\n\u003cp data-start=\"6437\" data-end=\"6506\"\u003eManagement of advanced cirrhosis complications remains a major focus.\u003c\/p\u003e\r\n\u003cp data-start=\"6508\" data-end=\"6523\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6524\" data-end=\"6638\"\u003e\r\n \t\u003cli data-section-id=\"v2xi81\" data-start=\"6524\" data-end=\"6546\"\u003eAscites management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1hicqvi\" data-start=\"6547\" data-end=\"6571\"\u003eHepatorenal syndrome\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"n0pgz\" data-start=\"6572\" data-end=\"6593\"\u003eVolume management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1690pn\" data-start=\"6594\" data-end=\"6609\"\u003eAlbumin use\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"9bxyb2\" data-start=\"6610\" data-end=\"6638\"\u003eRenal support strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6640\" data-end=\"6729\"\u003eClinical decision-making becomes particularly difficult in decompensated cirrhosis where:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6730\" data-end=\"6822\"\u003e\r\n \t\u003cli data-section-id=\"12yws6m\" data-start=\"6730\" data-end=\"6753\"\u003ePortal hypertension\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"lm7pbk\" data-start=\"6754\" data-end=\"6775\"\u003eRenal dysfunction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"2qpro0\" data-start=\"6776\" data-end=\"6794\"\u003eInfection risk\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"15qhxxs\" data-start=\"6795\" data-end=\"6822\"\u003eHemodynamic instability\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6824\" data-end=\"6853\"\u003eoften coexist simultaneously.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"jdbjzf\" data-start=\"6855\" data-end=\"6911\"\u003eLiver Transplant Selection \u0026amp; Advanced Hepatology Care\u003c\/h2\u003e\r\n\u003cp data-start=\"6913\" data-end=\"6950\"\u003eThe transplant board sessions review:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6951\" data-end=\"7081\"\u003e\r\n \t\u003cli data-section-id=\"t02kd\" data-start=\"6951\" data-end=\"6974\"\u003eCandidate selection\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1f5q771\" data-start=\"6975\" data-end=\"6998\"\u003eMELD prioritization\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"eom362\" data-start=\"6999\" data-end=\"7020\"\u003eContraindications\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1k1652h\" data-start=\"7021\" data-end=\"7047\"\u003eComorbidity assessment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"mhffol\" data-start=\"7048\" data-end=\"7081\"\u003eLong-term transplant outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7083\" data-end=\"7184\"\u003eAs liver disease therapies continue improving, transplant evaluation increasingly involves balancing:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"7185\" data-end=\"7298\"\u003e\r\n \t\u003cli data-section-id=\"dji6zf\" data-start=\"7185\" data-end=\"7220\"\u003eDisease reversibility potential\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ixst8j\" data-start=\"7221\" data-end=\"7243\"\u003eFrailty assessment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ntnw8u\" data-start=\"7244\" data-end=\"7263\"\u003eMalignancy risk\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"6h5toq\" data-start=\"7264\" data-end=\"7298\"\u003eCardiometabolic disease burden\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7300\" data-end=\"7381\"\u003eThe course appropriately emphasizes multidisciplinary transplant decision-making.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"9jcuf2\" data-start=\"7383\" data-end=\"7415\"\u003eReal-World Clinical Relevance\u003c\/h2\u003e\r\n\u003cp data-start=\"7417\" data-end=\"7501\"\u003eA major strength of the conference is its focus on clinically actionable hepatology.\u003c\/p\u003e\r\n\u003cp data-start=\"7503\" data-end=\"7535\"\u003eThe sessions repeatedly address:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"7536\" data-end=\"7758\"\u003e\r\n \t\u003cli data-section-id=\"1u6axw1\" data-start=\"7536\" data-end=\"7585\"\u003eTranslating clinical trial data into practice\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"19olphv\" data-start=\"7586\" data-end=\"7626\"\u003eEvidence-based therapeutic selection\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"lzux33\" data-start=\"7627\" data-end=\"7668\"\u003eLongitudinal liver disease management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"mkjhhg\" data-start=\"7669\" data-end=\"7696\"\u003eComplication prevention\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"61u4ro\" data-start=\"7697\" data-end=\"7726\"\u003ePersonalized patient care\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"29gyh1\" data-start=\"7727\" data-end=\"7758\"\u003eEmerging treatment pathways\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7760\" data-end=\"7838\"\u003eThe program reflects the reality that hepatology increasingly intersects with:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"7839\" data-end=\"7933\"\u003e\r\n \t\u003cli data-section-id=\"nxa76i\" data-start=\"7839\" data-end=\"7861\"\u003eMetabolic medicine\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"9obxko\" data-start=\"7862\" data-end=\"7874\"\u003eOncology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1p8j73c\" data-start=\"7875\" data-end=\"7894\"\u003eTransplantation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"owxzqg\" data-start=\"7895\" data-end=\"7909\"\u003eImmunology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"5yqvi0\" data-start=\"7910\" data-end=\"7933\"\u003ePreventive medicine\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"xydb7h\" data-start=\"7935\" data-end=\"7953\"\u003eWhat’s Included\u003c\/h2\u003e\r\n\u003cul data-start=\"7954\" data-end=\"8237\"\u003e\r\n \t\u003cli data-section-id=\"1fnntk0\" data-start=\"7954\" data-end=\"7993\"\u003e13 expert hepatology video lectures\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"p7onky\" data-start=\"7994\" data-end=\"8022\"\u003e13 subtitle files (.vtt)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"83qmz8\" data-start=\"8023\" data-end=\"8047\"\u003e12 downloadable PDFs\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1tt6wxt\" data-start=\"8048\" data-end=\"8071\"\u003eTotal size: 3.48 GB\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ebd0v7\" data-start=\"8072\" data-end=\"8099\"\u003eMASH and MetALD updates\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1tbbgnc\" data-start=\"8100\" data-end=\"8151\"\u003eViral hepatitis and delta hepatitis discussions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"cycl0x\" data-start=\"8152\" data-end=\"8188\"\u003eAutoimmune liver disease reviews\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1548z8s\" data-start=\"8189\" data-end=\"8237\"\u003eLiver transplant and HCC management sessions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"1uqeci3\" data-start=\"8239\" data-end=\"8266\"\u003eFinal Expert Perspective\u003c\/h2\u003e\r\n\u003cp data-start=\"8268\" data-end=\"8614\"\u003eModern hepatology is undergoing a major shift as advances in antiviral therapy, metabolic medicine, immunology, fibrosis reversal research, and liver transplantation continue reshaping patient care. Clinicians increasingly manage highly complex patients with overlapping metabolic, inflammatory, infectious, and oncologic liver disease processes.\u003c\/p\u003e\r\n\u003cp data-start=\"8616\" data-end=\"9101\"\u003eThe \u003cem data-start=\"8620\" data-end=\"8686\"\u003eScripps 40th Annual New Treatments in Chronic Liver Disease 2026\u003c\/em\u003e program provides a clinically grounded and up-to-date review of these developments through expert-led discussions focused on practical management, emerging therapeutics, and evolving disease classification. For hepatologists, gastroenterologists, and transplant specialists seeking advanced updates in chronic liver disease management, this course offers a highly relevant and evidence-driven educational resource.\u003c\/p\u003e\r\n\r\n\u003ch2 data-path-to-node=\"6\"\u003e Topics\u003c\/h2\u003e\r\n\u003col start=\"1\" data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003e01 The Emerging Clinical Entity of MetALD Diagnosis, Risk, and Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003e02 Treatment of MASH Cirrhosis Is it Reversible\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003e03 Obesity Treatment The Essentials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003e\u003cem\u003e\u003cstrong\u003e04 Pediatric MASH Approaches to Diagnosis and Treatment VIDEO PDF NOT RELEASE\u003c\/strong\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,4,0\"\u003e05 Panel Discussion Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,5,0\"\u003e06 Updates on Diagnosis and Treatment of Autoimmune Hepatitis\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,6,0\"\u003e07 Drug Induced Liver Injury\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,7,0\"\u003e08 Hepatitis B Functional Cures\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,8,0\"\u003e09 Using Medication Assisted Therapy in Hepatitis C\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,9,0\"\u003e10 Delta Hepatitis\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,10,0\"\u003e11 Panel Discussion Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,11,0\"\u003e\u003cem\u003e\u003cstrong\u003e12 HCC VIDEO PDF NOT RELEASE\u003c\/strong\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,12,0\"\u003e13 Transplant Selection Board\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,13,0\"\u003e14 WILLIAM S. HAUBRICH LECTURE Updates in PBC and PSC\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,14,0\"\u003e15 Panel Discussion Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ol\u003e","brand":"Amboss","offers":[{"title":"Default Title","offer_id":42954732896354,"sku":"MED-AMB08968","price":30.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Scripps-40th-Annual-New-Treatments-in-Chronic-Liver-Disease-2026_cfd76e10-ca6f-46f3-9153-07789478e63d.png?v=1779383349","url":"https:\/\/meducourse.com\/products\/scripps-40th-annual-new-treatments-in-chronic-liver-disease-2026-20","provider":"Meducourse","version":"1.0","type":"link"}